671 related articles for article (PubMed ID: 26314551)
1. The distribution of BRAF gene fusions in solid tumors and response to targeted therapy.
Ross JS; Wang K; Chmielecki J; Gay L; Johnson A; Chudnovsky J; Yelensky R; Lipson D; Ali SM; Elvin JA; Vergilio JA; Roels S; Miller VA; Nakamura BN; Gray A; Wong MK; Stephens PJ
Int J Cancer; 2016 Feb; 138(4):881-90. PubMed ID: 26314551
[TBL] [Abstract][Full Text] [Related]
2. Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131).
Johnson DB; Zhao F; Noel M; Riely GJ; Mitchell EP; Wright JJ; Chen HX; Gray RJ; Li S; McShane LM; Rubinstein LV; Patton D; Williams PM; Hamilton SR; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
Clin Cancer Res; 2020 Apr; 26(8):1812-1819. PubMed ID: 31924734
[TBL] [Abstract][Full Text] [Related]
3. Trametinib in metastatic melanoma.
Chopra N; Nathan PD
Expert Rev Anticancer Ther; 2015; 15(7):749-60. PubMed ID: 26107021
[TBL] [Abstract][Full Text] [Related]
4. Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy.
Botton T; Yeh I; Nelson T; Vemula SS; Sparatta A; Garrido MC; Allegra M; Rocchi S; Bahadoran P; McCalmont TH; LeBoit PE; Burton EA; Bollag G; Ballotti R; Bastian BC
Pigment Cell Melanoma Res; 2013 Nov; 26(6):845-51. PubMed ID: 23890088
[TBL] [Abstract][Full Text] [Related]
5. Improved survival with MEK inhibition in BRAF-mutated melanoma.
Flaherty KT; Robert C; Hersey P; Nathan P; Garbe C; Milhem M; Demidov LV; Hassel JC; Rutkowski P; Mohr P; Dummer R; Trefzer U; Larkin JM; Utikal J; Dreno B; Nyakas M; Middleton MR; Becker JC; Casey M; Sherman LJ; Wu FS; Ouellet D; Martin AM; Patel K; Schadendorf D;
N Engl J Med; 2012 Jul; 367(2):107-14. PubMed ID: 22663011
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes.
Chmielecki J; Hutchinson KE; Frampton GM; Chalmers ZR; Johnson A; Shi C; Elvin J; Ali SM; Ross JS; Basturk O; Balasubramanian S; Lipson D; Yelensky R; Pao W; Miller VA; Klimstra DS; Stephens PJ
Cancer Discov; 2014 Dec; 4(12):1398-405. PubMed ID: 25266736
[TBL] [Abstract][Full Text] [Related]
7. Pilot Study of a Next-Generation Sequencing-Based Targeted Anticancer Therapy in Refractory Solid Tumors at a Korean Institution.
Park HS; Lim SM; Kim S; Kim S; Kim HR; Kwack K; Lee MG; Kim JH; Moon YW
PLoS One; 2016; 11(4):e0154133. PubMed ID: 27105424
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors.
Menzies AM; Wilmott JS; Drummond M; Lo S; Lyle M; Chan MM; Thompson JF; Guminski A; Carlino MS; Scolyer RA; Kefford RF; Long GV
Cancer; 2015 Nov; 121(21):3826-35. PubMed ID: 26218930
[TBL] [Abstract][Full Text] [Related]
9. Analysis of IDH1-R132 mutation, BRAF V600 mutation and KIAA1549-BRAF fusion transcript status in central nervous system tumors supports pediatric tumor classification.
Gierke M; Sperveslage J; Schwab D; Beschorner R; Ebinger M; Schuhmann MU; Schittenhelm J
J Cancer Res Clin Oncol; 2016 Jan; 142(1):89-100. PubMed ID: 26115961
[TBL] [Abstract][Full Text] [Related]
10. Molecular characterization of disseminated pilocytic astrocytomas.
Gessi M; Engels AC; Lambert S; Rothämel T; von Hornstein S; Collins VP; Denkhaus D; Gnekow A; Pietsch T
Neuropathol Appl Neurobiol; 2016 Apr; 42(3):273-8. PubMed ID: 26084390
[TBL] [Abstract][Full Text] [Related]
11. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
12. Detection of KIAA1549-BRAF fusion transcripts in formalin-fixed paraffin-embedded pediatric low-grade gliomas.
Tian Y; Rich BE; Vena N; Craig JM; Macconaill LE; Rajaram V; Goldman S; Taha H; Mahmoud M; Ozek M; Sav A; Longtine JA; Lindeman NI; Garraway LA; Ligon AH; Stiles CD; Santagata S; Chan JA; Kieran MW; Ligon KL
J Mol Diagn; 2011 Nov; 13(6):669-77. PubMed ID: 21884820
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma.
Cin H; Meyer C; Herr R; Janzarik WG; Lambert S; Jones DT; Jacob K; Benner A; Witt H; Remke M; Bender S; Falkenstein F; Van Anh TN; Olbrich H; von Deimling A; Pekrun A; Kulozik AE; Gnekow A; Scheurlen W; Witt O; Omran H; Jabado N; Collins VP; Brummer T; Marschalek R; Lichter P; Korshunov A; Pfister SM
Acta Neuropathol; 2011 Jun; 121(6):763-74. PubMed ID: 21424530
[TBL] [Abstract][Full Text] [Related]
14. Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma.
Parakh S; Murphy C; Lau D; Cebon JS; Andrews MC
J Clin Pharm Ther; 2015 Feb; 40(1):121-3. PubMed ID: 25382067
[TBL] [Abstract][Full Text] [Related]
15. BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy.
Sloot S; Zager JS; Kudchadkar RR; Messina JL; Benedict JJ; Gonzalez RJ; DeConti R; Turner LM; McCardle T; Smalley KS; Weber JS; Sondak VK; Gibney GT
Melanoma Res; 2016 Feb; 26(1):83-7. PubMed ID: 26731560
[TBL] [Abstract][Full Text] [Related]
16. Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein.
Subbiah V; Westin SN; Wang K; Araujo D; Wang WL; Miller VA; Ross JS; Stephens PJ; Palmer GA; Ali SM
J Hematol Oncol; 2014 Jan; 7():8. PubMed ID: 24422672
[TBL] [Abstract][Full Text] [Related]
17. B-Raf Inhibition in the Clinic: Present and Future.
Fiskus W; Mitsiades N
Annu Rev Med; 2016; 67():29-43. PubMed ID: 26768236
[TBL] [Abstract][Full Text] [Related]
18. Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing.
Selt F; Hohloch J; Hielscher T; Sahm F; Capper D; Korshunov A; Usta D; Brabetz S; Ridinger J; Ecker J; Oehme I; Gronych J; Marquardt V; Pauck D; Bächli H; Stiles CD; von Deimling A; Remke M; Schuhmann MU; Pfister SM; Brummer T; Jones DT; Witt O; Milde T
Oncotarget; 2017 Feb; 8(7):11460-11479. PubMed ID: 28002790
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status.
Broecker-Preuss M; Müller S; Britten M; Worm K; Schmid KW; Mann K; Fuhrer D
BMC Cancer; 2015 Mar; 15():184. PubMed ID: 25879531
[TBL] [Abstract][Full Text] [Related]
20. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
Menzies AM; Long GV
Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
